0730-0735

Welcome Remarks

Lolita T. O’Donnell, Ph.D., M.S.N., R.N.
Division Chief, Leadership Education Analysis Development Sustainment (LEADS) Division
Academic Superintendent, Continuing Education Program Office (CEPO), J-7, Education and Training (E&T) Directorate, Defense Health Agency (DHA)
Falls Church, Va.

−

0735-0745

Opening Remarks

Paul Cordts, M.D.
Deputy Assistant Director
Medical Affairs, DHA
Falls Church, Va.

 −

Moderator

U.S. Public Health Service Capt. Anne K. McMillan, D.N.P., M.S.N., F.N.P.-B.C., C.L.N.C.
DHA Program Manager, Women's Health Clinical Management Team (HCMT)
DHA, Medical Affairs
Falls Church, Va.

−

0745-0845

Department of Veterans Affairs (VA)/Department of Defense (DoD) Collaboration in Women’s Mental Health: Available Resources for  Female Service Members Transitioning from Active Service

Kimberly Lahm, L.M.F.T.
Program Director, Patient Advocacy & Experience, Women's, Child & Family Health Policy, Office of Assistant Secretary of Defense (OASD) of Health Affairs, DHHQ
Falls Church, Va.

Holly N. O’Reilly, Ph.D.
Acting Section Chief, Implementation
Clinical Care, Psychological Health Center of Excellence (PHCoE), J-9 Research and Development, DHA
Silver Spring, Md.

Jennifer Strauss, Ph.D.
Program Manager, National Women’s Mental Health
Office of Mental Health and Suicide Prevention
Department of Veterans Affairs (VA)
Durham, N.C.

1. Describe two resources that Service members may utilize to mitigate the negative outcomes associated with transition to civilian status.
2. Explain the importance of providing support to Service members as they transition from Active Duty status.
3. List at least two ways that female Veterans’ mental health problems can differ from those experienced by male Veterans.
4. Discuss at least two ways that VA mental health care has been designed to meet women Veterans’ treatment needs.
5. Identify at least two ways that women Veterans can learn more about accessing VA services.

0845-0855

Break

0855-0955

Intimate Partner Violence: Effects on Women’s Health

 Navy Cmdr. Monica A. Lutgendorf, M.D., F.A.C.O.G.
  Chair, Women and Infant Clinical Community, DHA
  Associate Residency Program Director, Obstetrics and
  Gynecology (OB/GYN)
  Associate Professor, Uniformed Services University (USU)
  Division Head, Maternal Fetal Medicine (MFM)
  Naval Medical Center San Diego (NMCSD)
  San Diego, Calif.

1. Define intimate partner violence (IPV).
2. Recognize intimate partner violence.
3. Screen patients for intimate partner violence.
4. Support and manage patients experiencing intimate partner violence.
5. Explain reporting requirements for intimate partner violence.

0955-1005

Break

1005-1105

Human Papillomavirus: Opportunity to Eradicate Gynecologic Dysplasia and Cancer

Army Maj. Erica R Hope, M.D.
Attending Physician, Gynecologic Oncology
Assistant Professor, Gynecologic Surgery & Obstetrics
F. Edward Hebert School of Medicine, USU
Brooke Army Medical Center (BAMC)
San Antonio, Texas

1. Identify human papillomavirus (HPV) as a cause of gynecologic dysplasia and malignancy.
2. Summarize the burden of HPV-related dysplasia and cancer on the medical system.
3. Evaluate HPV vaccine as a cancer prevention method.
4. Assess avenues to increase HPV vaccination rates.

1105-1115

Break

1115-1215

Women and Cardiovascular Conditions: A Macro and Micro Look

Janine A. Clayton, M.D.
Associate Director, Research on Women’s Health
Director, Office of Research on Women’s Health
National Institutes of Health (NIH)
Bethesda, Md.

Gina Wei, M.D., M.P.H.
Associate Director, Division of Cardiovascular Sciences
Director, Prevention and Population Sciences Program
National Heart, Lung, and Blood Institute
National Institutes of Health (NIH)
Bethesda, Md.

1. Review the origin of the NIH Office of Research on Women’s Health and the principles and strategic priorities that guide women’s health research across the NIH.
2. Describe how women are less likely to receive appropriate treatment for cardiovascular disease (CVD) because they manifest CVD differently than men do. 
3. Discuss the rising rate of maternal mortality in the United States, its disproportionate impact on racial and ethnic minority groups, and CVD as a leading cause of maternal deaths.
4. Explain how COVID-19 can affect the cardiovascular system and how the coronavirus disproportionately affects women, people of color, and other vulnerable populations.
5. Identify opportunities throughout the life course of women for promoting cardiovascular health, including before, during and after reproductive years.
6. Select from a wide range of available resources including toolkits and guidelines to promote cardiovascular health in women.

1215-1315

Break

1315-1415

Management of COVID-19 in Pregnancy

Navy Lt. Cmdr. Michael Miller, M.D.
Clinical Fellow, Johns Hopkins Hospital
Baltimore, Md.

Arthur Jason Vaught, M.D.
Assistant Professor, Department of Gynecology and Obstetrics (OB/GYN), Division of Maternal Fetal Medicine (MFM)
Assistant Professor, Department of Surgery, Division of Trauma, Acute Care Surgery, and Surgical Critical Care
The Johns Hopkins University School of Medicine
Baltimore, Md.

1. Describe the Centers for Disease Control and Prevention (CDC) recommendations for the use of remdesivir in treating COVID-19.
2. Explain the CDC recommendations for the use of dexamethasone in treating COVID-19.
3. Comprehend and apply the appropriate escalation of supplemental oxygen in patients with COVID-19.
4. Recognize indications for escalation of care to the intensive care unit (ICU) for patients with COVID-19.

1415-1425

Break

1425-1525

Ethical Challenges in Women’s Health Care During the COVID-19 Pandemic

Megan K. Applewhite M.D., M.A., F.A.C.S.
Associate Professor, Surgery
Chair, John A. Balint M.D. Medical Ethics
Director, Alden March Bioethics Institute
Albany Medical College, Albany, N.Y.
Consultant Bioethicist, DoD Medical Ethics Center
USU Bethesda, Md.

1. Identify the ethical challenges for women’s health care that have been highlighted by the COVID-19 pandemic.
2. Outline how cessation of nonessential cases was deleterious to the reproductive rights of women.
3. Explain the theoretical risks of categorizing abortions to as “elective” procedures.

1525-1535

Break

1535-1635

Updates on Select DHA Women and Infants Clinical Community Initiatives

Army Lt. Col. Kelly Beeken, M.D., F.A.C.O.G.
Co-lead, WICC Levels of Maternal Care Working Group, DHA
Assistant Department Chief, OB/GYN
Madigan Army Medical Center (MAMC)
Joint Base Lewis-McChord, Wash.

Army Lt. Col. Erin Keyser, M.D., F.A.C.O.G.
Army Representative, DHA WICC
Residency Program Director, OB/GYN
Associate Professor, USU BAMC,
San Antonio, Texas

  Navy Cmdr. Shannon Lamb, M.D.
  Lead, WICC Walk-In Contraception, DHA
  Navy OB/GYN Specialty Leader
  Staff Urogynecologist, WRNMMC
  Bethesda, Md.

  Navy Cmdr. Monica A. Lutgendorf, M.D., F.A.C.O.G.
  Chair, Women and Infant Clinical Community, DHA
  Associate Residency Program Director, OB/GYN
  Associate Professor, USU
  Division Head, MFM, Naval Medical Center San Diego
  San Diego, Calif.

Air Force Lt. Col. Krista Mehlhaff, D.O., F.A.C.O.G.
Co-lead, WICC Severe Maternal Morbidity and Mortality Working Group (SMMM WG), DHA
Physician, MFM, Perinatal Assessment Center
Walter Reed National Military Medical Center (WRNMMC)
Bethesda, Md.

Air Force Lt. Col. Larissa Weir, M.D., F.A.C.O.G.
Air Force Representative, WICC, DHA
Air Force Surgeon General Chief Women's Health Consultant
Associate Professor, USU
Air Force Medical Readiness Agency
Falls Church, Va.

Air Force Maj. Heather Hubbard, D.N.P, A.P.R.N., W.H.N.P.-B.C., C.N.E.
Co-lead, WICC SMMM WG, DHA
Flight Commander, Family Care, 9th Medical Group
Beale Air Force Base, Calif.

Theresa Hart, M.S., R.N., N.C.C.-E.
Program Manager, WICC
Senior Nurse Consultant, Special Medical Programs
Medical Affairs, DHA
Arlington, Va.

1. Explain the importance of process standardization with decreased non-beneficial clinical variation.
2. List examples of improved obstetrical/gynecological outcomes with clinical process standardization.
3. Identify at least one opportunity for improvement in their own clinic or facility from the projects presented.

1635-1645

Closing Remarks

Air Force Brig. Gen. Anita Fligge, D.N.P., R.N., N.E.A.-B.C.
Deputy Assistant Director (DAD), J-7 E&T Directorate
Chief Nursing Officer, Defense Health Agency (DHA)
Falls Church, Va.

−